Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

A. M. M. Eggermont, V. Chiarion-Sileni, J. J. Grob, R. Dummer, J. D. Wolchok, H. Schmidt, O. Hamid, C. Robert, P. A. Ascierto, J. M. Richards, C. Lebbe, V. Ferraresi, M. Smylie, J. S. Weber, M. Maio, F. Hosein, V. de Pril, M. Kicinski, S. Suciu, A. Testori

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Since 2015, adjuvant therapy with ipilimumab is an approved treatment for stage III melanoma based on a significantly prolonged recurrence-free survival (RFS). At a median follow-up of 5.3 years, RFS, distant metastasis-free survival (DMFS) and overall survival (OS) were each significantly prolonged in the ipilimumab group compared with the placebo group, despite a 53.3% (ipilimumab) versus 4.6% (placebo) treatment discontinuation rate due to adverse events. We present now long-term follow-up results of this European Organisation for Research and Treatment of Cancer 18071 trial. PATIENTS, METHODS AND RESULTS: A total of 99 sites randomised 951 patients with stage III cutaneous melanoma (excluding lymph node metastasis
Original languageItalian
Pages (from-to)1-10
Number of pages10
JournalEuropean Journal of Cancer
Publication statusPublished - 2019

Cite this